Upgrade to SI Premium - Free Trial

Atossa Therapeutics (ATOS)

2.37 -0.11 (4.44%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/16/26)

Latest Headlines

Atossa Genetics (ATOS) Tops Q2 EPS by 10c August 7, 2026 8:59 AM - StreetInsider Form 8-K ATOSSA THERAPEUTICS, For: Aug 07 August 7, 2026 8:45 AM - SEC Filing Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update August 7, 2026 8:45 AM - PR NewsWire Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30 August 7, 2026 8:31 AM - SEC Filing Atossa preclinical study on endoxifen compounds published in npj July 28, 2026 8:30 AM - StreetInsider Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer July 28, 2026 8:30 AM - PR NewsWire Atos achieves CMMC 2.0 Level 2 certification, strengthening readiness for mission-critical and complex defense programs July 23, 2026 12:59 PM - Globe NewsWire Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers July 21, 2026 8:30 AM - PR NewsWire Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy July 7, 2026 7:50 AM - StreetInsider Full Article List